Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice?

Pathology

Volumn 47, Issue 4, 2015, Pages 386-388

  Harris, P N A ^a   Alder, L ^b   Paterson, D L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; CLINICAL PRACTICE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMAN; INFECTIOUS DISEASE MEDICINE; METHODOLOGY; QUESTIONNAIRE; STANDARDS; STATISTICS AND NUMERICAL DATA;

ANTI-INFECTIVE AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MICROBIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INFECTIOUS DISEASE MEDICINE; PRACTICE PATTERNS, PHYSICIANS'; RESEARCH DESIGN; SURVEYS AND QUESTIONNAIRES;

EID: 84978744401     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000255     Document Type: Article

References (8)

1. 1. Jacoby, G.A., AmpC beta-lactamases. Clin Microbiol Rev 22 (2009), 161–182.
2. 2. Chow, J.W., Fine, M.J., Shlaes, D.M., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115 (1991), 585–590.
3. 3. Choi, S.H., Lee, J.E., Park, S.J., et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 52 (2008), 995–1000.
4. 4. Harris, P.N., Ferguson, J.K., Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?. Int J Antimicrob Agents 40 (2012), 297–305.
5. 5. Kaye, K.S., Cosgrove, S., Harris, A., et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Anti-microb Agents Chemother 45 (2001), 2628–2630.
6. 6. Cosgrove, S.E., Kaye, K.S., Eliopoulous, G.M., et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 162 (2002), 185–190.
7. 7. Goldstein, F.W., Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clinical Microbiol Infect 8 (2002), 823–825.
8. 8. Schwaber, M.J., Graham, C.S., Sands, B.E., et al. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother 47 (2003), 1882–1886.